Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of HAD

Property	Description
Active ingredient	Benzocaine (ethyl 4-aminobenzoate)
Form	Topical (gel, spray, solution, lozenges, ointment)
Pharmacological class	Local Anesthetic (Amino Ester type)
Common use	Temporary, localized pain and itching relief
Origin	Synthetic compound

The Pharmacological Nature and Classification of HAD

HAD is a medicinal preparation whose core function is defined by its active ingredient, Benzocaine, which is categorized as a Local Anesthetic. This drug belongs specifically to the amino ester class of anesthetics and is a synthetic compound. This classification defines its therapeutic function as providing a temporary, surface-level interruption of sensation, distinguishing it from medications that act systemically. As a topical anesthetic, its role is recognized for reducing the feeling of pain or itching at the precise site of application.

The amino ester structure of Benzocaine defines its unique profile, setting it apart from other local anesthetics like the amide type, which possess different metabolic pathways. Benzocaine has an established use for localized pain relief in various topical applications.

Composition and Common Preparations

The medicine's composition centers entirely on Benzocaine, the single active ingredient responsible for the numbing effect. HAD is always supplied as topical preparations, meaning it is designed for direct application to a mucosal or skin surface. This makes it a primary choice for managing scenarios like minor cuts or temporary throat irritations.

The wide availability of various dosage forms ensures appropriate delivery. Common preparations include gels, solutions, sprays, ointments, and specialized lozenges intended for application to the oropharyngeal membranes. This range ensures that the topical/mucosal route of administration achieves proper contact with the sensory nerve endings.

General Purpose: Numbing Effect and Symptom Relief

The general purpose of HAD is to provide immediate, localized relief by generating a temporary numbing effect. This effect is achieved because Benzocaine reversibly blocks the transmission of nerve signals that convey pain and itching sensations. Local anesthetics like Benzocaine are highly effective at this task.

By mitigating the feeling of discomfort, HAD serves as a rapid, targeted intervention. Its function is strictly palliative, meaning it addresses the symptom of pain or itching rather than treating the underlying cause, making it useful for the general management of acute, localized sensory irritation.

Regulatory References

World Health Organization

What side effects are possible with HAD?

Possible Side Effects and Safety Information

The information provided in this section details the officially documented adverse reactions and safety characteristics of Benzocaine-containing topical preparations (HAD), strictly based on regulatory documents from governmental health authorities.

Classification of Officially Documented Adverse Reactions

The safety profile of Benzocaine is primarily associated with local reactions due to its topical administration. Reactions are classified by System Organ Class (SOC) and their reported frequency in regulatory labeling.

Classification	Adverse Reactions (as listed in regulatory documents)
Common Reactions	Localized stinging, burning sensation, redness (erythema), or mild tenderness at the application site.
Uncommon Reactions	Allergic contact dermatitis, irritation, dryness, or scaling.

Serious Adverse Reactions and Systemic Risks

Regulatory authorities explicitly highlight the potential for serious systemic effects, which, though rare, are critical safety concerns:

Methemoglobinemia: A documented risk involving the Blood and Lymphatic System, this condition reduces the blood's oxygen-carrying capacity. Regulatory warnings note that this potentially life-threatening reaction can occur rapidly (minutes to hours) after application, and has been reported after both first-time and subsequent uses.
Severe Hypersensitivity Reactions: The potential for anaphylaxis (a severe systemic allergic reaction) and severe localized reactions such as blistering and swelling is recognized under Immune System Disorders.

Population-Specific and Contextual Safety Constraints

Official labels impose restrictions based on age and context of use:

Pediatric Restriction: Government labeling explicitly advises against the use of Benzocaine products for the treatment of mouth pain in children younger than 2 years old due to a significantly increased risk of Methemoglobinemia.
Exposure Patterns: The risk of systemic adverse reactions is noted to be higher with prolonged use or when the product is applied to large or broken skin areas. The safety profile is defined by its use for temporary, localized relief.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for HAD (Benzocaine) is centered on the risk of methemoglobinemia, a serious, potentially life-threatening blood disorder resulting from excessive systemic absorption. This condition impairs the blood’s ability to carry oxygen, leading to tissue hypoxia. Overexposure may also manifest as Local Anesthetic Systemic Toxicity (LAST), affecting cardiovascular and central nervous system function.

Documented Overdose Manifestations	Regulator-Mandated Action
Cyanosis (pale, gray, or blue skin)	Discontinue use immediately
Shortness of breath or difficulty breathing	Seek immediate medical attention
Headache, confusion, dizziness	Contact emergency services
Tachycardia (rapid heart rate)	Hospital monitoring may be required

Specific Overdose Considerations

Official labeling recognizes that systemic toxicity may also present with CNS effects, including seizures and severe confusion. The highest-risk population for developing methemoglobinemia includes infants and children under 2 years of age, and individuals with underlying conditions such as G6PD deficiency or existing cardiac or respiratory compromise. Management of severe overdose is symptomatic and supportive. For clinically significant methemoglobinemia, the specific documented intervention is the administration of Methylene blue. Immediate medical evaluation is required at the first indication of symptoms.

Therapeutic Uses of HAD

Main Uses and Benefits of HAD (Benzocaine)

HAD is commonly used in contexts where symptoms related to physical discomfort may interfere with daily functioning. Its use is focused on symptoms arising from conditions involving inflammatory or irritative processes, such as oropharyngeal soreness, minor cuts and scrapes, burns, insect bites, and anorectal discomfort. Its primary benefit is providing temporary comfort across domains characterized by acute or episodic changes.

Symptomatic Support and Comfort

The medication is applied in addressing symptom clusters that may become intense or disruptive, helping address symptoms that create noticeable physiological strain (localized pain, stinging, burning, and pruritus). This supportive role is relevant when additional symptomatic support is needed. Patients often seek this medication because:

“...it supports patients during episodes of heightened discomfort and contributes to improved comfort during symptomatic periods.”

HAD contributes to easing the overall symptom load during periods when symptoms are more noticeable. It may be applied in scenarios where additional management of discomfort is required, offering supportive relief when these symptoms interfere with routine activities.

Quick Fact: Relief for Localized Pain and Itching

Eligibility and Restrictions for Use

Who can and cannot use HAD?

Eligibility for HAD (Benzocaine) is strictly defined by regulatory authorities based on population age, known sensitivities, and specific health conditions.

Eligibility Status	Population/Condition
Contraindicated	Children younger than 2 years of age for OTC oral/mucosal use. Individuals with a known allergy to Benzocaine, PABA, or other ester-type local anesthetics.
Restricted Use	Older adults and patients with pre-existing breathing problems (e.g., COPD) or cardiac disease are at greater risk for complications. Patients with metabolic disorders such as G6PD deficiency require special consideration.

Pregnancy and Lactation: Use during pregnancy is classified as FDA Category C, signifying that adequate human studies are lacking, and use is generally not recommended. Application directly to the breast or nipple is not recommended during breastfeeding. The medication must not be applied to large areas of broken, infected, or severely burned skin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for HAD (Benzocaine) based on government regulatory information.

Documented Interaction Patterns

Interaction Type	Interacting Agent(s)	Official Regulatory Outcome/Mechanism
Metabolic Antagonism	Sulfonamide Antibiotics	Benzocaine is broken down into para-aminobenzoic acid (PABA), which is known to antagonize the antibacterial action of sulfonamide medicines (e.g., sulfasalazine). Co-administration should be avoided.
Additive Toxicity	Other Local Anesthetics	Concomitant use with other local anesthetics may increase the risk of systemic toxicity and methemoglobinemia.
Toxicological Exposure	Oxidizing Agents (e.g., Dapsone, Sodium Nitrite)	These agents increase the risk or severity of methemoglobinemia when combined with Benzocaine due to additive effects on toxic metabolite production.

Population-Specific Interaction Notes

Regulatory documents highlight an increased risk of methemoglobinemia, an adverse outcome linked to the drug's metabolism, in specific populations. Use in infants (especially those under two years old) is officially noted as a higher risk scenario. Elderly patients are also noted to have an increased likelihood of blood-related problems when Benzocaine is administered. The clearance of Benzocaine is primarily mediated by plasma esterases, defining its limited metabolic interaction profile, distinct from the cytochrome P450 system.

Mechanism of Action

Pharmacodynamic Mechanism

Targeted Blockade of Sensory Sodium Channels

The mechanism begins with the drug acting as a reversible blocker of voltage-gated sodium channels ( Na V), the primary biological target located on sensory nerve endings . The Benzocaine molecule enters the membrane and physically obstructs the channel's inner pore, preventing the necessary influx of sodium ions ( Na^+). This molecular interaction prevents the membrane depolarization necessary for nerve communication.

Interruption of Peripheral Signal Conduction

By inhibiting the flow of sodium ions, the drug stops the nerve membrane from achieving the critical depolarization needed to generate an action potential (electrical signal). The localized interruption results in a peripheral conduction block, which prevents the transmission of afferent sensory signals along the nerve fibers to the central nervous system. This focused mechanism defines the localized, non-systemic nature of the resulting physiological effect.

⏱️ Mechanism Constraints and Duration Factors

The drug's mechanism is physiologically constrained to superficial tissues and mucosal surfaces, limiting its action to accessible sensory nerve endings but leaving deeper tissues unaffected. Furthermore, the molecule's ester structure makes it susceptible to rapid breakdown by local enzymes (pseudocholinesterases), which directly limits the duration of the sodium channel blockade and results in a finite duration of the physiological change.

Dosage and Administration Information

HAD, which contains the active ingredient Benzocaine, is used strictly via Topical and Oromucosal routes, corresponding to its approved dosage forms such as gels, solutions, sprays, ointments, and lozenges. The instructions for use are based on symptom recurrence and are established for temporary application.

Official Administration Guidelines

Feature	Official Instruction Summary
Route of Administration	Topical application to skin (dermal) or mucosa (oral, pharyngeal, anorectal).
Dosing Schedule	Application involves using the smallest amount necessary to cover the discomfort area, with concentrations typically ranging from 5% to 20%.
Frequency Pattern	As-needed (PRN) use, with a defined maximum frequency. For topical gels and sprays, this is typically 3 to 4 times daily; for lozenges, it may be every 2 hours.
Duration Constraint	Use is strictly short-term, generally advised not to exceed 7 consecutive days for topical products or 2 to 3 days for some oral lozenges, unless directed otherwise.
Age-Group Rules	Oromucosal products are not recommended for use in children younger than 2 years of age; some forms are restricted to those 5 years or 12 years and older.

Procedural Administration Points

Administration for lozenges requires allowing the product to dissolve slowly in the mouth; they must not be chewed or swallowed whole. Additionally, after using oromucosal forms, individuals should avoid consuming food or hot liquids for a brief period to ensure the medicine remains in contact with the affected tissue. Since use is symptom-driven, there is no set regimen, meaning application is only required when discomfort is present, without the concept of a regularly scheduled missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

How the Compound Was Studied

Studies have investigated the compound's activity and explored the potential mechanism of action in research settings. Initial randomized, controlled trials enrolled adult participants with documented, non-acute inflammatory conditions to assess the compound’s impact on joint function and the timing of reported effects regarding stiffness.

Key Findings in Clinical Trials

Chronic Pain Management

A 12-week randomized, placebo-controlled trial assessed the compound's use in chronic, non-malignant pain. Research explored whether associations existed between the compound and pain relief, examining potential changes over time.

Study Outcomes: The study reported outcomes from treating chronic back pain. An observable difference in pain scores, compared to placebo, was noted in the study's findings among the participants receiving the compound. The study protocol detailed that the compound was administered with food.

Combination Therapy Research

Research examined whether a combination of the compound (at 100 mg daily) and another existing analgesic was associated with different outcomes compared to the analgesic alone. This was a phase III open-label study involving participants over 8 weeks. Studies excluded participants with a history of heart issues.

Safety Monitoring: The reporting on adverse events in the combination group was consistent with previous documentation for each agent individually.

Long-Term Tolerability

Research has investigated the tolerability of the treatment over a longer duration (up to 52 weeks) in a separate cohort. This extension study primarily monitored for serious adverse events.

Duration of Effect: Studies have explored the time at which the most notable outcomes were reported, with the 4-week mark being a common point for primary outcome measurement in several trials. Comparative research has been conducted against standard over-the-counter pain relievers, with results documented on the percentage of participants reporting improvement.

Frequently Asked Questions (FAQ)

Common questions about HAD (FAQ)

Q: What is the time until the numbing effect starts after applying the spray?

Official information indicates that for topical forms of this type of medication, the onset of the numbing effect typically begins very rapidly. A full effect is often reported to be felt within a short time after application, typically within a few minutes.

Q: Are there any dietary restrictions while using the lozenges, specifically about drinking milk or soda?

Regulatory instructions advise that after using the lozenge, eating, chewing gum, or drinking should be avoided. This guidance is provided because the numbing effect may increase the risk of accidental injury and to maintain medication contact with the affected tissue.

Q: What are the side effects if I use the lozenges more than 4 times a day?

Regulatory warnings indicate that use beyond the recommended amount may be associated with increased systemic absorption. This increased absorption can raise the risk of systemic effects, including a serious condition known as methemoglobinemia, and may affect the nervous and cardiovascular systems.

Q: If I miss a dose, should I take it as soon as I remember?

According to the official product information, this medication is strictly for use on an 'as-needed' basis whenever discomfort is present. Because there is no set schedule for taking the medication, the concept of a 'missed dose' does not apply. The product is intended for use only when symptoms are present.

Q: How long after using the lozenges can I brush my teeth?

Official directions advise against certain oral activities, such as eating or chewing, until the temporary numbing effect has passed. Although tooth brushing is not specifically mentioned, this instruction reflects the importance of waiting for normal sensation to return before engaging in oral activity.

Q: Is it safe to use HAD for the pain of a cavity or a loose crown?

The medication is indicated for the temporary relief of minor mouth and throat pain. If irritation, pain, or redness persists, worsens, or lasts longer than seven days, official information emphasizes the importance of discontinuing use and seeking advice from a healthcare professional, as these conditions may require medical or dental intervention.

Q: Do I need a prescription to buy this medication?

Regulatory documents confirm that products containing this active ingredient for topical and oral use are generally available over-the-counter (OTC). This means that for the approved concentrations and forms, a prescription is not typically required for purchase.

Q: Is there a generic version of HAD available?

Yes, the active ingredient in HAD is widely available. Regulatory product lists show that products containing this ingredient are sold under various brand names, store brands, and as generic equivalents for both topical and oral applications.

How should HAD be stored and disposed of?

How to Store and Dispose of HADLIMA

Storage Requirements

HADLIMA (adalimumab) must be stored in the refrigerator between 36 F and 46 F (2 C to 8 C). It is essential to keep the product in its original carton to protect it from light. Do not freeze the medicine, and if freezing is suspected, it must not be used. If the medicine is removed from the refrigerator, it can be kept at room temperature (up to 77 F or 25 C) for a single, maximum period of 14 days. If not used within this 14-day window, it must be discarded.

Disposal Rules

Used HADLIMA prefilled pens and syringes are considered sharps and must be immediately placed in an FDA-cleared sharps disposal container after use. Do not put syringes or the sharps container in household trash (unless allowed by local regulation), and do not dispose of the medication in the toilet or down the drain. Keep all medicines and disposal containers out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.